Table 2.

Association of synovial fluid CD163 and CD14 concentrations with OA phenotypes^*

	Synovial fluid CD163		Synovial fluid CD14
OA phenotype	β (95% CI)†	P	β (95% CI)†	P
Activated macrophages in joint capsule‡	0.989 (0.368, 1.610)	0.005	1.293 (0.569, 2.016)	0.002
Activated macrophages in synovium‡	1.442 (0.625, 2.259)	0.002	1.806 (0.955, 2.657)	0.0005
Osteophyte severity‡	2.820 (1.524, 4.116)	0.0003	3.473 (2.121, 4.825)	<0.0001
Osteophyte severity§	0.093 (−0.132, 0.319)	0.418	0.686 (0.433, 0.939)	<0.0001
JSN severity‡	0.422 (−0.048, 0.892)	0.093	0.608 (0.116, 1.099)	0.025
JSN severity§	0.042 (−0.003, 0.087)	0.066	0.098 (0.007, 0.189)	0.035
Osteophyte progression§	0.072 (0.020, 0.123)	0.007	0.096 (0.039, 0.185)	0.015
Osteophyte progression§¶	0.056 (0.027, 0.085)	<0.0001	0.043 (−0.030, 0.115)	0.246
JSN progression§	0.006 (−0.013, 0.026)	0.528	0.006 (−0.040, 0.052)	0.802
JSN progression§#	0 (−0.017, 0.016)	0.975	−0.018 (−0.061, 0.025)	0.411

^*OA = osteoarthritis; β = parameter estimate (based on CD163 and CD14 concentrations in µg/ml); 95% CI = 95% confidence interval.

^†Adjusted for age, sex, and body mass index.

^‡Etarfolatide scan cohort.

^§Prediction of Osteoarthritis Progression cohort.

^¶Adjusted for age, sex, body mass index, and baseline osteophyte severity.

^#Adjusted for age, sex, body mass index, and baseline joint space narrowing (JSN) severity.